WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 慢性骨髄性白血病の治療の概要 overview of the treatment of chronic myeloid leukemia
2. 血管新生阻害剤の概要 overview of angiogenesis inhibitors
3. GISTを含む消化管間葉系腫瘍の疫学、分類、臨床像、予後の特徴、および診断方法 epidemiology classification clinical presentation prognostic features and diagnostic work up of gastrointestinal mesenchymal neoplasms including gist
4. 慢性骨髄性白血病に対するチロシンキナーゼ阻害剤の臨床使用 clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia
5. 進行消化管間質腫瘍に対するチロシンキナーゼ阻害剤療法 tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors

Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.

Orlova A1, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S, Tolmachev V, Löfblom J.
European journal of nuclear medicine and molecular imaging.Eur J Nucl Med Mol Imaging.2014 Jul;41(7):1450-9. doi: 10.1007/s00259-014-2733-7. Epub 2014 Mar 13.
PURPOSE: Human epidermal growth factor receptor type 3 (HER3) is a transmembrane receptor tyrosine kinase belonging to the HER (ErbB) receptor family. Membranous expression of HER3 is associated with trastuzumab resistance in breast cancer and the transition to androgen independence in prostate canc
PMID 24622956

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Fu W1, Wang Y2, Zhang Y3, Xiong L2, Takeda H4, Ding L2, Xu Q5, He L2, Tan W6, Bethune AN7, Zhou L2.
mAbs.MAbs.2014 Jul 1;6(4):978-90. doi: 10.4161/mabs.28786. Epub 2014 Apr 16.
HER2, a ligand-free tyrosine kinase receptor of the HER family, is frequently overexpressed in breast cancer. The anti-HER2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer; however, resistance to trastuzumab is common. The development of monoclonal antibodies
PMID 24838231

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Wang YJ1, Kathawala RJ1, Zhang YK1, Patel A1, Kumar P1, Shukla S2, Fung KL2, Ambudkar SV2, Talele TT1, Chen ZS3.
Biochemical pharmacology.Biochem Pharmacol.2014 Jun 14. pii: S0006-2952(14)00349-9. doi: 10.1016/j.bcp.2014.06.006. [Epub ahead of print]
Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are responsible for the development of MDR, preeminent among them being the accelerated drug efflux mediated by overexpression of ATP binding cassette (ABC) transporters. Som
PMID 24937702